drugset / Trial / NCT06175390
Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase II study, preceded by a safety run-in, with two independent cohorts (cohort A in early Triple Negative Breast Cancer (TNBC) patients and cohort B in late in metastatic TNBC patients) designed to evaluate the efficacy of atezolizumab, tiragolumab and chemotherapy.
Timeline
- Start
- 2024-03-27
- Primary completion
- 2026-08-15
- Completion
- 2029-02-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Atezolizumab | Monoclonal antibody | 1680 mg | Intravenous |
| Subject | Carboplatin | Small molecule | 5 unknown | — |
| Subject | Cyclophosphamide | Other / unclassified | 600 mg/m2 | — |
| Subject | Doxorubicin | Other / unclassified | 60 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Tiragolumab | Monoclonal antibody | 600 mg | Intravenous |
| Subject | Tiragolumab | Monoclonal antibody | 840 mg | Intravenous |
| Background | Olaparib | Small molecule | — | — |